A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer

PD-1/PD-L1-inhibiting antibodies have shown disappointing efficacy in patients with refractory ovarian cancer (OC). Apparently, OC cells exploit nonoverlapping immunosuppressive mechanisms to evade the immune system. In this respect, the CD73-adenosine inhibitory immune checkpoint is of particular i...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers 2023-07, Vol.15 (14), p.3651
Hauptverfasser:	Ploeg, Emily Maria, Britsch, Isabel, van Wijngaarden, Anne Paulien, Ke, Xiurong, Hendriks, Mark Alexander Johannes Martinus, Samplonius, Douwe Freerk, Helfrich, Wijnand
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Antibodies Antigens Antitumor activity Bispecific antibodies Blocking antibodies Cancer therapies CD73 antigen Cell growth Cell surface Cisplatin Cytotoxicity Development and progression Doxorubicin Effector cells Enzymatic activity Enzymes Flow cytometry Immune checkpoint Immune system Immunosuppression Immunotherapy Inflammation Ionizing radiation Lymphocytes T Medical prognosis Ovarian cancer Patients PD-1 protein PD-L1 protein Plasmids T cells Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!